ClinicalTrials.gg
CompletedNCT06026202Updated Nov 6, 2026Results posted

Non-Eosinophilic Biological Effects of IL-5

An observational study in Asthma, sponsored by Imperial College London. Completed at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Imperial College London · Observational

How we know

Updated Nov 6, 2026Now CompletedResults posted+7 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
8
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 46 studies in Asthma by Imperial College London — 4 open to participants now, 4 under way, none of them phase 3. Asthma · Imperial College London.

Enrollment
16th of 17
8 · median 66
Started
2023
with 1 other
Observational
17 of 46
4 open now
Registered
45th of 46
by date

Among the 46 studies in Asthma by Imperial College London, this one is the 16th largest by enrollment of the 17 observational ones that give a count, is one of 2 that started in 2023, is one of 17 observational ones, and was the 45th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

4 of the 46 studies in Asthma by Imperial College London are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies in Asthma by Imperial College London, or all of them as a file.
02

Study summary

This study aims to investigate the role of IL-5 in suppressing anti-viral immune responses in bronchial epithelial cells (BECs) and in peripheral blood mononuclear cells (PBMCs) from 5 people with asthma.

Read the detailed description

IL-5 has been shown to be present in higher levels in those with asthma, more so during viral infection. The investigators know from existing evidence that having increased levels of interferon (IFN) reduces asthma exacerbations and viral load. The investigators suspect that IL-5 reduces the immune response during viral infection in bronchial epithelial cells (BECs) and peripheral blood mononuclear cells (PBMCs) by reducing levels of IFN. The aim is to investigate if increased IL-5 in stable eosinophilic asthma and asthma exacerbations suppresses anti-viral immunity in bronchial epithelial cells and in peripheral blood mononuclear cells directly via IL-5 receptor signalling, suppressing rhinovirus induction of IFNs. The investigators also will evaluate if anti-IL-5 therapies suppress IL-5 concentrations in stable and exacerbated asthma in vivo and whether suppression of IL-5 in vivo restores deficient anti-viral immunity in BECs and PBMCs, thereby protecting against asthma exacerbations.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • Interleukin 5
  • Bronchial epithelial cells
  • Peripheral blood mononuclear cells
  • Peripheral dendritic cells
  • Interferon
  • Rhinovirus
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Those with mild asthma on as required salbutamol only.

Eligibility criteria

Must be eligible for the study 'Mechanisms of Adverse Effects of Long-Acting Beta-Agonists in Asthma' (MAELABA) (19SM5101).

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
8 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. IFNB1 Expression in PBMCs Following IL-5 Treatment and RV-A16 Infection (MOI 1)

    Peripheral blood mononuclear cells (PBMCs) isolated from participants with asthma were pretreated ex vivo with IL-5 and infected with rhinovirus A16 (RV-A16) at MOI 1. IFNB1 mRNA expression was measured by quantitative PCR 8 hours after infection.

    Time frame: 8 hours post infection

  2. IFNB1 Expression in Bronchial Epithelial Cells (BECs) Infected With RV-A16 (MOI 1) Following IL-5 Treatment

    Bronchial epithelial cells (BECs) isolated from participants with asthma were pretreated ex vivo with IL-5 and infected with rhinovirus A16 (RV-A16) at MOI 1. IFNB1 mRNA expression was measured by quantitative PCR 8 hours after infection.

    Time frame: 8 hours post infection

Secondary outcomes

  1. IFN-β Protein Production in PBMCs Infected With RV-A16 (MOI 1) Following IL-5 Treatment

    Peripheral blood mononuclear cells (PBMCs) isolated from participants with asthma were pretreated ex vivo with IL-5 and infected with rhinovirus A16 (RV-A16) at MOI 1. IFN-β protein levels were measured in cell culture supernatants 24 hours after infection.

    Time frame: 24 hours after RV-A16 infection

  2. IFN-β Protein Production in BECs Infected With RV-A16 (MOI 1) Following IL-5 Treatment

    Bronchial epithelial cells (BECs) isolated from participants with asthma were pretreated ex vivo with IL-5 and infected with rhinovirus A16 (RV-A16) at MOI 1. IFN-β protein levels were measured in cell culture supernatants 24 hours after infection.

    Time frame: 24 hours after RV-A16 infection

  3. IL5RA Expression in PBMCs Infected With RV-A16 (MOI 1) Following IL-5 Treatment

    Peripheral blood mononuclear cells (PBMCs) isolated from participants with asthma were pretreated ex vivo with IL-5 and infected with rhinovirus A16 (RV-A16) at MOI 1. IL5RA mRNA expression was measured by quantitative PCR 8 hours after infection.

    Time frame: 8 hours after RV-A16 infection

  4. IL5RA Expression in BECs Infected With RV-A16 (MOI 1) Following IL-5 Treatment

    Bronchial epithelial cells (BECs) isolated from participants with asthma were pretreated ex vivo with IL-5 and infected with rhinovirus A16 (RV-A16) at MOI 1. IL5RA mRNA expression was measured by quantitative PCR 8 hours after infection.

    Time frame: 8 hours after RV-A16 infection

  5. CSF2RB Expression in PBMCs Infected With RV-A16 (MOI 1) Following IL-5 Treatment

    Peripheral blood mononuclear cells (PBMCs) isolated from participants with asthma were pretreated ex vivo with IL-5 and infected with rhinovirus A16 (RV-A16) at MOI 1. CSF2RB mRNA expression was measured by quantitative PCR 8 hours after infection.

    Time frame: 8 hours after RV-A16 infection

  6. CSF2RB Expression in BECs Infected With RV-A16 (MOI 1) Following IL-5 Treatment

    Bronchial epithelial cells (BECs) isolated from participants with asthma were pretreated ex vivo with IL-5 and infected with rhinovirus A16 (RV-A16) at MOI 1. CSF2RB mRNA expression was measured by quantitative PCR 8 hours after infection.

    Time frame: 8 hours after RV-A16 infection

  7. RV-A16 Viral RNA Levels in PBMCs Infected With RV-A16 (MOI 1) Following IL-5 Treatment

    Peripheral blood mononuclear cells (PBMCs) isolated from participants with asthma were pretreated ex vivo with IL-5 and infected with rhinovirus A16 (RV-A16) at MOI 1. RV-A16 viral RNA levels were quantified by quantitative PCR 8 hours after infection.

    Time frame: 8 hours after RV-A16 infection

  8. RV-A16 Viral RNA Levels in BECs Infected With RV-A16 (MOI 1) Following IL-5 Treatment

    Bronchial epithelial cells (BECs) isolated from participants with asthma were pretreated ex vivo with IL-5 and infected with rhinovirus A16 (RV-A16) at MOI 1. RV-A16 viral RNA levels were quantified by quantitative PCR 8 hours after infection.

    Time frame: 8 hours after RV-A16 infection

07

Results

Posted Nov 6, 2026

Participant flow

Participants with asthma were recruited and enrolled to provide blood and bronchial epithelial cell samples for ex vivo studies investigating the effects of interleukin-5 (IL-5) on antiviral responses to rhinovirus A16 (RV-A16).

Participant flow — Overall Study
MilestoneAsthma Participants
Started8
Completed8
Not completed0

Outcome measures

PrimaryIFNB1 Expression in PBMCs Following IL-5 Treatment and RV-A16 Infection (MOI 1)

Peripheral blood mononuclear cells (PBMCs) isolated from participants with asthma were pretreated ex vivo with IL-5 and infected with rhinovirus A16 (RV-A16) at MOI 1. IFNB1 mRNA expression was measured by quantitative PCR 8 hours after infection.

Time frame:
8 hours post infection
Reported as:
Mean · copies/µL cDNA
IFNB1 Expression in PBMCs Following IL-5 Treatment and RV-A16 Infection (MOI 1)
copies/µL cDNAAsthma Participants
IL-5 0 ng/mL1808 ± 3384
IL-5 10 ng/mL1333 ± 2329
IL-5 50 ng/mL1206 ± 2309
IL-5 100 ng/mL1396 ± 2599
PrimaryIFNB1 Expression in Bronchial Epithelial Cells (BECs) Infected With RV-A16 (MOI 1) Following IL-5 Treatment

Bronchial epithelial cells (BECs) isolated from participants with asthma were pretreated ex vivo with IL-5 and infected with rhinovirus A16 (RV-A16) at MOI 1. IFNB1 mRNA expression was measured by quantitative PCR 8 hours after infection.

Time frame:
8 hours post infection
Reported as:
Mean · copies/µL cDNA
IFNB1 Expression in Bronchial Epithelial Cells (BECs) Infected With RV-A16 (MOI 1) Following IL-5 Treatment
copies/µL cDNAAsthma Participants
IL-5 0 ng/mL40.35 ± 46.69
IL-5 10 ng/mL67.14 ± 115.1
IL-5 50 ng/mL115.3 ± 215.5
IL-5 100 ng/mL93.84 ± 117.2
SecondaryIFN-β Protein Production in PBMCs Infected With RV-A16 (MOI 1) Following IL-5 Treatment

Peripheral blood mononuclear cells (PBMCs) isolated from participants with asthma were pretreated ex vivo with IL-5 and infected with rhinovirus A16 (RV-A16) at MOI 1. IFN-β protein levels were measured in cell culture supernatants 24 hours after infection.

Time frame:
24 hours after RV-A16 infection
Reported as:
Mean · pg/mL
IFN-β Protein Production in PBMCs Infected With RV-A16 (MOI 1) Following IL-5 Treatment
pg/mLAsthma Participants
IL-5 0 ng/mL271.5 ± 178.2
IL-5 10 ng/mL332.6 ± 215.1
IL-5 50 ng/mL313.1 ± 161.9
IL-5 100 ng/mL352.9 ± 92.8
SecondaryIFN-β Protein Production in BECs Infected With RV-A16 (MOI 1) Following IL-5 Treatment

Bronchial epithelial cells (BECs) isolated from participants with asthma were pretreated ex vivo with IL-5 and infected with rhinovirus A16 (RV-A16) at MOI 1. IFN-β protein levels were measured in cell culture supernatants 24 hours after infection.

Time frame:
24 hours after RV-A16 infection
Reported as:
Mean · pg/mL
IFN-β Protein Production in BECs Infected With RV-A16 (MOI 1) Following IL-5 Treatment
pg/mLAsthma Participants
IL-5 0 ng/mL4.71 ± 6.153
IL-5 10 ng/mL1.501 ± 1.797
IL-5 50 ng/mL5.813 ± 7.26
IL-5 100 ng/mL2.811 ± 2.897
SecondaryIL5RA Expression in PBMCs Infected With RV-A16 (MOI 1) Following IL-5 Treatment

Peripheral blood mononuclear cells (PBMCs) isolated from participants with asthma were pretreated ex vivo with IL-5 and infected with rhinovirus A16 (RV-A16) at MOI 1. IL5RA mRNA expression was measured by quantitative PCR 8 hours after infection.

Time frame:
8 hours after RV-A16 infection
Reported as:
Mean · copies/µL cDNA
IL5RA Expression in PBMCs Infected With RV-A16 (MOI 1) Following IL-5 Treatment
copies/µL cDNAAsthma Participants
IL-5 0 ng/mL13.4 ± 20.77
IL-5 10 ng/mL4.742 ± 11.62
IL-5 50 ng/mL2.829 ± 6.929
IL-5 100 ng/mL0 ± 0
SecondaryIL5RA Expression in BECs Infected With RV-A16 (MOI 1) Following IL-5 Treatment

Bronchial epithelial cells (BECs) isolated from participants with asthma were pretreated ex vivo with IL-5 and infected with rhinovirus A16 (RV-A16) at MOI 1. IL5RA mRNA expression was measured by quantitative PCR 8 hours after infection.

Time frame:
8 hours after RV-A16 infection
Reported as:
Mean · copies/µL cDNA
IL5RA Expression in BECs Infected With RV-A16 (MOI 1) Following IL-5 Treatment
copies/µL cDNAAsthma Participants
IL-5 0 ng/mL12.07 ± 12.77
IL-5 10 ng/mL39.86 ± 47.91
IL-5 50 ng/mL9.747 ± 14.47
IL-5 100 ng/mL28.79 ± 62.04
SecondaryCSF2RB Expression in PBMCs Infected With RV-A16 (MOI 1) Following IL-5 Treatment

Peripheral blood mononuclear cells (PBMCs) isolated from participants with asthma were pretreated ex vivo with IL-5 and infected with rhinovirus A16 (RV-A16) at MOI 1. CSF2RB mRNA expression was measured by quantitative PCR 8 hours after infection.

Time frame:
8 hours after RV-A16 infection
Reported as:
Mean · copies/µL cDNA
CSF2RB Expression in PBMCs Infected With RV-A16 (MOI 1) Following IL-5 Treatment
copies/µL cDNAAsthma Participants
IL-5 0 ng/mL484.6 ± 373.7
IL-5 10 ng/mL217.2 ± 267.9
IL-5 50 ng/mL683.5 ± 948.7
IL-5 100 ng/mL124.4 ± 203.4
SecondaryCSF2RB Expression in BECs Infected With RV-A16 (MOI 1) Following IL-5 Treatment

Bronchial epithelial cells (BECs) isolated from participants with asthma were pretreated ex vivo with IL-5 and infected with rhinovirus A16 (RV-A16) at MOI 1. CSF2RB mRNA expression was measured by quantitative PCR 8 hours after infection.

Time frame:
8 hours after RV-A16 infection
Reported as:
Mean · copies/µL cDNA
CSF2RB Expression in BECs Infected With RV-A16 (MOI 1) Following IL-5 Treatment
copies/µL cDNAAsthma Participants
IL-5 0 ng/mL286.7 ± 486.8
IL-5 10 ng/mL14.33 ± 31.94
IL-5 50 ng/mL68.91 ± 147.4
IL-5 100 ng/mL55.49 ± 99.87
SecondaryRV-A16 Viral RNA Levels in PBMCs Infected With RV-A16 (MOI 1) Following IL-5 Treatment

Peripheral blood mononuclear cells (PBMCs) isolated from participants with asthma were pretreated ex vivo with IL-5 and infected with rhinovirus A16 (RV-A16) at MOI 1. RV-A16 viral RNA levels were quantified by quantitative PCR 8 hours after infection.

Time frame:
8 hours after RV-A16 infection
Reported as:
Mean · copies/µL cDNA
RV-A16 Viral RNA Levels in PBMCs Infected With RV-A16 (MOI 1) Following IL-5 Treatment
copies/µL cDNAAsthma Participants
IL-5 0 ng/mL2718153 ± 5783089
IL-5 10 ng/mL1227172 ± 2389034
IL-5 50 ng/mL1223239 ± 2564335
IL-5 100 ng/mL1810980 ± 3577180
SecondaryRV-A16 Viral RNA Levels in BECs Infected With RV-A16 (MOI 1) Following IL-5 Treatment

Bronchial epithelial cells (BECs) isolated from participants with asthma were pretreated ex vivo with IL-5 and infected with rhinovirus A16 (RV-A16) at MOI 1. RV-A16 viral RNA levels were quantified by quantitative PCR 8 hours after infection.

Time frame:
8 hours after RV-A16 infection
Reported as:
Mean · copies/µL cDNA
RV-A16 Viral RNA Levels in BECs Infected With RV-A16 (MOI 1) Following IL-5 Treatment
copies/µL cDNAAsthma Participants
IL-5 0 ng/mL6782114 ± 7302029
IL-5 10 ng/mL8171611 ± 6618586
IL-5 50 ng/mL5758877 ± 3566248
IL-5 100 ng/mL8118634 ± 7264645

Adverse events

Collected over Adverse events were monitored during bronchoscopy and the immediate post-procedure recovery period, until participants had returned to their normal level of consciousness, had stable vital signs, and were able to swallow, in accordance with hospital guidelines. This usually took around 2 hours. Follow-up assessments were also conducted 1 week after bronchoscopy.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Asthma Participants0/8 (0%)0/8 (0%)0/8 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)Asthma Participants
Mean30.25 ± 11.54
Sex: Female, Male
Sex: Female, Male(Participants)Asthma Participants
Female6
Male2
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Asthma Participants
American Indian or Alaska Native0
Asian3
Native Hawaiian or Other Pacific Islander0
Black or African American1
White4
More than one race0
Unknown or Not Reported0
Fractional exhaled nitric oxide (FeNO)
Fractional exhaled nitric oxide (FeNO)(ppb (parts per billion))Asthma Participants
Mean50.25 ± 35.81
08

Study locations

1 site
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2023 to primary completion in Dec 2025, 27 months.

Results were first posted in Nov 2026, 10 months after primary completion.

Of 366 non-industry observational studies under Asthma, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 97. This study's 27 months is below that.

Counting every sponsor, half of 456 studies reached it within 36 months; a quarter within 18 and three quarters within 82.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 6, 2026: primary completion Sep 2024 → Dec 2025 and completion Sep 2024 → Dec 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2023
First posted
Sep 7, 2023
StartActual
Sep 1, 2023
Primary completionActual
Dec 22, 2025was Sep 2024
CompletionActual
Dec 22, 2025was Sep 2024
Results first posted
Nov 6, 2026
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 6, 2026
Results
Results posted
posted Nov 6, 2026
Sites
1 site added, 1 site removed
Show site
  • Imperial College London · London, United Kingdom
Show 1 removed
  • Imperial College London · London, United Kingdom
Nov 6, 2026
Primary completion
Sep 30, 2024→Dec 22, 2025 (actual)
Nov 6, 2026
Study completion
Sep 30, 2024→Dec 22, 2025 (actual)
Nov 6, 2026
Enrollment
5 (estimated)→8 (actual)
Nov 6, 2026
Primary outcomes
2 added, 1 removed
What changed in the outcomes
  • AddedIFNB1 Expression in PBMCs Following IL-5 Treatment and RV-A16 Infection (MOI 1)Time frame: 8 hours post infection
  • AddedIFNB1 Expression in Bronchial Epithelial Cells (BECs) Infected With RV-A16 (MOI 1) Following IL-5 TreatmentTime frame: 8 hours post infection
  • RemovedIL-5 suppresses anti-viral immunity in BECs and in PBMCs/pDCs directly via IL-5 receptor signalling suppressing RV induction of IFNs.Time frame: 1 year
Nov 6, 2026
Secondary outcomes
8 added
What changed in the outcomes
  • AddedIFN-β Protein Production in PBMCs Infected With RV-A16 (MOI 1) Following IL-5 TreatmentTime frame: 24 hours after RV-A16 infection
  • AddedIFN-β Protein Production in BECs Infected With RV-A16 (MOI 1) Following IL-5 TreatmentTime frame: 24 hours after RV-A16 infection
  • AddedIL5RA Expression in PBMCs Infected With RV-A16 (MOI 1) Following IL-5 TreatmentTime frame: 8 hours after RV-A16 infection
  • AddedIL5RA Expression in BECs Infected With RV-A16 (MOI 1) Following IL-5 TreatmentTime frame: 8 hours after RV-A16 infection
  • AddedCSF2RB Expression in PBMCs Infected With RV-A16 (MOI 1) Following IL-5 TreatmentTime frame: 8 hours after RV-A16 infection
  • AddedCSF2RB Expression in BECs Infected With RV-A16 (MOI 1) Following IL-5 TreatmentTime frame: 8 hours after RV-A16 infection
  • AddedRV-A16 Viral RNA Levels in PBMCs Infected With RV-A16 (MOI 1) Following IL-5 TreatmentTime frame: 8 hours after RV-A16 infection
  • AddedRV-A16 Viral RNA Levels in BECs Infected With RV-A16 (MOI 1) Following IL-5 TreatmentTime frame: 8 hours after RV-A16 infection
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Recruiting→Completed
    Results posted
    1 site added, 1 site removed
    Show site
    • Imperial College London · London, United Kingdom
    Show 1 removed
    • Imperial College London · London, United Kingdom
    Primary completion Sep 30, 2024→Dec 22, 2025 (now actual)
    Study completion Sep 30, 2024→Dec 22, 2025 (now actual)
    Enrollment 5 (estimated)→8 (actual)
    Primary outcomes 2 added, 1 removed
    What changed in the outcomes
    • AddedIFNB1 Expression in PBMCs Following IL-5 Treatment and RV-A16 Infection (MOI 1)Time frame: 8 hours post infection
    • AddedIFNB1 Expression in Bronchial Epithelial Cells (BECs) Infected With RV-A16 (MOI 1) Following IL-5 TreatmentTime frame: 8 hours post infection
    • RemovedIL-5 suppresses anti-viral immunity in BECs and in PBMCs/pDCs directly via IL-5 receptor signalling suppressing RV induction of IFNs.Time frame: 1 year
    Secondary outcomes 8 added
    What changed in the outcomes
    • AddedIFN-β Protein Production in PBMCs Infected With RV-A16 (MOI 1) Following IL-5 TreatmentTime frame: 24 hours after RV-A16 infection
    • AddedIFN-β Protein Production in BECs Infected With RV-A16 (MOI 1) Following IL-5 TreatmentTime frame: 24 hours after RV-A16 infection
    • AddedIL5RA Expression in PBMCs Infected With RV-A16 (MOI 1) Following IL-5 TreatmentTime frame: 8 hours after RV-A16 infection
    • AddedIL5RA Expression in BECs Infected With RV-A16 (MOI 1) Following IL-5 TreatmentTime frame: 8 hours after RV-A16 infection
    • AddedCSF2RB Expression in PBMCs Infected With RV-A16 (MOI 1) Following IL-5 TreatmentTime frame: 8 hours after RV-A16 infection
    • AddedCSF2RB Expression in BECs Infected With RV-A16 (MOI 1) Following IL-5 TreatmentTime frame: 8 hours after RV-A16 infection
    • AddedRV-A16 Viral RNA Levels in PBMCs Infected With RV-A16 (MOI 1) Following IL-5 TreatmentTime frame: 8 hours after RV-A16 infection
    • AddedRV-A16 Viral RNA Levels in BECs Infected With RV-A16 (MOI 1) Following IL-5 TreatmentTime frame: 8 hours after RV-A16 infection
    + 3 other changes: verification date, contact details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06026202
Responsible party
Sponsor
First posted
Sep 7, 2023
Start date
Sep 1, 2023
Primary completion
Dec 22, 2025
Completion
Dec 22, 2025
Results posted
Nov 6, 2026
Last update
Nov 6, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion